Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179071 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04179071 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 16 participants.
The verdict
NCT04179071, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This will be an open-label, randomised, 2 part (Part A and Part B), 2 treatment (savolitinib alone or in combination with famotidine), crossover study in healthy, non Japanese, male subjects, performed at a single study centre.
Interventions
- DRUG Famotidine
- DRUG Savolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179071
The ClinicalTrials.gov registry entry for NCT04179071 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Famotidine is the first listed.
NCT04179071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04179071 about?
NCT04179071 is a clinical study titled "A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine". This will be an open-label, randomised, 2 part (Part A and Part B), 2 treatment (savolitinib alone or in combination with famotidine), crossover study in healthy, non Japanese, male subjects, performed at a single study centre.
What is the current status of trial NCT04179071?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-12-13. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT04179071?
The interventions under investigation include: Famotidine (DRUG), Savolitinib (DRUG).
Who is sponsoring clinical trial NCT04179071?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.